Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.04 per share
-
Shares outstanding
-
106,324,269
-
Total 13F shares
-
20,737,577
-
Share change
-
-878,445
-
Total reported value
-
$15,488,034
-
Price per share
-
$0.74
-
Number of holders
-
40
-
Value change
-
-$756,614
-
Number of buys
-
13
-
Number of sells
-
24
Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value EUR0.04 per share (PRQR) as of Q3 2022
As of 30 Sep 2022,
ProQR Therapeutics N.V. - Ordinary Shares, nominal value EUR0.04 per share (PRQR) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,737,577 shares.
The largest 10 holders included
Privium Fund Management B.V., ADAGE CAPITAL PARTNERS GP, L.L.C., Opaleye Management Inc., Prosight Management, LP, M28 Capital Management LP, Monaco Asset Management SAM, FIL Ltd, DAFNA Capital Management LLC, MACQUARIE GROUP LTD, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
40
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.